Clifford Chance, Maples and Calder JunHe advised SciClone Pharmaceuticals on its US$281 million initial public offering and listing on the main board of the Hong Kong...
SciClone Pharmaceuticals’ Hong Kong Initial Public Offering And Listing
JD.com’s US$3.87 Billion Hong Kong IPO And Secondary Listing
Clifford Chance has advised the joint sponsors Bank of America, UBS and CLSA, and the underwriters on JD.com’s US$3.87 billion initial public offeringand secondary listing on...